If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
336
results.
Updated on
20/08/2026 [07:44:00]
Results 100 to 125 of 336
Absstract of: CN122468955A
0001 本发明公开一种基于量子点荧光纳米球标记的单分子免疫检测法（QD‑based SMIA），属于生物检测技术领域。本发明所述检测方法用于体液中低浓度生物标志物的超灵敏检测，突破现有检测技术的灵敏度瓶颈，为疾病的早期筛查、病情监测及疗效评估提供一种简单、经济、可靠的检测手段。本发明使用的量子点荧光纳米球是包埋荧光量子点的单分散聚合物纳米球，可保护量子点在使用过程中不受外界因素干扰并放大荧光检测信号，明显提高检测灵敏度。本发明选用流式细胞仪作为检测手段，可以对量子点荧光纳米球进行绝对计数，实现生物标志物分子的单分子检测和多指标联合检测，提高检测结果的特异性，并降低检测成本。
Absstract of: CN122465035A
0001 本发明属于分子诊断与蛋白质工程技术领域，公开了一种低自聚集倾向的重组α‑突触核蛋白及其在制备神经退行性疾病α‑syn‑RT‑QuIC检测系统中的应用，该重组α‑突触核蛋白由含α‑突触核蛋白和插入野生型α‑突触核蛋白第1位氨基酸M位点之后、氨基酸序列如SEQ ID NO:1所示的多肽组成。本发明旨在克服现有野生型α‑突触核蛋白单体在α‑syn‑RT‑QuIC检测中因自发聚集而产生高背景噪声、导致假阳性及检测特异性下降的缺陷。检测时，该重组α‑突触核蛋白可显著降低非特异性聚集信号，提高对病理性α‑突触核蛋白种子活性的检测灵敏度和特异性，从而为神经退行性疾病的早期诊断和生物标志物检测提供更可靠的工具。
Absstract of: MX2026000543A
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD, based on presence of antimicrobial peptides (AMPs) at levels that differ from those in control individuals.
Absstract of: CA3137909A1
0001 The present disclosure relates to the use of an anti-IL6 receptor antibody for treating rheumatoid arthritis in subjects with serum concentrations of certain biomarkers. 0002 La présente invention concerne l'utilisation d'un anticorps anti-récepteur d'IL6 pour traiter la polyarthrite rhumatoïde chez des sujets présentant des concentrations sériques de certains biomarqueurs.
Absstract of: AU2024292030A1
Provided is the use of urinary C5b-9 (uC5b-9) as a highly accurate and superior biomarker well correlated with complement activity in local tissues affected by complement-mediated diseases (e.g., those with a kidney damage component). The biomarker is useful, for example, in treating and/or monitoring such complement-mediated diseases, using complement inhibitors targeted to such local tissues affected by the diseases, without systemic complement inhibition.
Absstract of: CN122444868A
0001 本发明具体涉及一种靶向焦谷氨酸Aβ的单域抗体及其制备方法和应用，所述单域抗体的氨基酸序列SEQ ID NO.1或SEQ ID NO.2或SEQ ID NO.3或SEQ ID NO.4或SEQ ID NO.5或SEQ ID NO.6 或SEQ ID NO.7或SEQ ID NO.8所示；以条纹斑竹鲨作为免疫对象，采用PE‑Aβ为抗原进行免疫，提取免疫鲨鱼外周血细胞的总RNA，逆转录为cDNA，以cDNA为模板进行扩增，与噬菌粒载体构建重组噬菌粒载体，转入感受态细胞中，扩大培养，筛选阳性克隆，得到所述单域抗体。本发明提供的单域抗体，能够特异性识别PEAβ，具有良好的结合活性，且分子量小，解决了目前尚未有靶向PEAβ的鲨鱼纳米抗体的技术问题，为后续研究该抗体在PEAβ的检测中的应用奠定了重要基础，具有开发检测PEAβ的试剂或治疗PEAβ相关疾病的药物的应用前景。
Absstract of: KR20260115290A
0001a 본 발명은 구리 이온 탐지 및 전달을 위한 탄소 나노입자에 관한 것으로 구체적으로는 황이 탄소와 섞여 있어 구리 이온을 탐지할 수 있고, 구리 이온을 내부에 포집하고 있어 생체 내로 구리 이온을 전달할 수 있는 나노입자에 관한 것이다.
Absstract of: CN122440826A
本发明公开了一种C/EBPβ和/或CXCL10作为靶点在脓毒症相关脑病的诊断与治疗中的应用，涉及生物医学领域。本发明首次揭示了一条在脓毒症相关脑病中驱动神经炎症与认知损伤的新信号通路：转录因子C/EBPβ通过直接结合并激活CXCL10的转录，进而诱导小胶质细胞发生NLRP3炎性小体介导的焦亡。焦亡的小胶质细胞释放大量炎症因子，导致神经元突触损伤与凋亡，最终引发认知功能障碍。基于此，本发明提出了将C/EBPβ和CXCL10作为治疗SAE的药物靶点（如开发其抑制剂或中和抗体）以及作为辅助诊断SAE的生物标志物的全新用途，为SAE的防治提供了新的策略和工具。
Absstract of: WO2021127549A1
Disclosed herein are methods for making a transcriptome-wide expression profile of a biological sample and identifying biomarkers that can be used to diagnose, monitor the onset, monitor the progression, and assess the recovery of a disease in a subject. The biomarkers can also be used to establish and evaluate treatment regimens.
Absstract of: CN122444867A
本发明公开了检测神经丝轻链蛋白的抗体及其应用，具体涉及检测神经丝轻链蛋白的抗体和试剂盒，基于该抗体及试剂盒能够准确的检测神经丝轻链蛋白的存在。
Absstract of: CN122449140A
本发明公开了一种吖啶酯标记复合物，包括本体，标记于本体上的标记基团，所述本体为抗体，所述标记基团为吖啶酯类基团。一种吖啶酯标记复合物制备方法，包括以下步骤：吸取标记缓冲液至离心管中；吸取待标记的抗体至离心管中并混匀，生成第一混合溶液；加入吖啶酯溶液并混匀，在25℃下避光反应2小时，生成第二反应溶液；加入终止缓冲液并混匀，在25℃下避光反应30分钟，生成第三反应溶液；对第三反应溶液进行脱盐纯化，生成第四混合溶液；将第四混合溶液用0.22μm滤膜进行过滤，生成吖啶酯标记复合物。本发明的制备方法，吖啶酯与抗体的标记效率更高，反应性更强；非特异性吸附更低，灵敏度更高，重复性和稳定性更好，且标记方法简单快速易重复。
Absstract of: CN122445789A
0001 一种试剂盒及RNF40在制备检测类风湿关节炎相关帕金森病产品中的应用，该试剂盒包含用于特异性检测RNF40基因或蛋白表达水平的检测组分。本发明基于大规模人群队列分析、孟德尔随机化研究、多组织转录组筛选及动物共病模型体内功能验证，首次发现RNF40在类风湿关节炎与帕金森病关联轴上呈现双向介导特征，类风湿关节炎患者外周血等样本中RNF40表达水平显著低于参考值时，其发生帕金森病的风险增高。该试剂盒通过体外无创检测实现类风湿关节炎患者帕金森病风险的分层评估，还可通过连续监测RNF40表达变化进行动态预警，具有操作简便、适于大规模筛查的特点，为临床早期干预和精准管理提供了可靠工具。
Absstract of: US20260210980A1
The present invention relates to a splice variant of an ICA1 protein that acts as a biomarker for a TDP-43 pathology. In particular, the present invention relates to methods for identifying a splice variant of ICA1 comprising a cryptic peptide sequence, and to related methods of identifying a TDP-43 pathology and/or reduced TDP-43 function in a subject.
Absstract of: US20260207777A1
0000 Compositions and methods are provided for enhancing homology-directed repair in gene-editing applications using improved inhibitors of 53BP1.
Absstract of: US20260209296A1
Tau reporter compositions, tau reporter cells, and tau reporter animals are provided that comprise a four-repeat (4R) tau isoform linked to a first reporter protein and a three-repeat (3R) tau isoform linked to a second reporter protein that is different from the first reporter protein. Methods are provided for making such tau reporter cells and tau reporter animals and for using such tau reporter cells and tau reporter animals for assessing the activity of tau-targeting reagents.
Absstract of: US20260210981A1
Disclosed herein are antibodies or antigen-binding fragments thereof and compositions comprising the same. Also disclosed are methods of detecting TAR DNA-binding protein 43 (TDP-43) in a biological sample, diagnosing a neurodegenerative disease in a subject, and selecting whether to enroll a subject in a clinical trial for frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) using the antibodies or antigen-binding fragments thereof described herein. In addition, disclosed herein are immunoassay kits for selectively detecting TDP-43 in a biological sample.
Absstract of: US20260209322A1
0000 The present specification provides a monoclonal antibody that specifically binds aggregated, non-phosphorylated α-synuclein and a hybridoma producing it. Also disclosed are methods of generating antibodies that specifically binds aggregated, non-phosphorylated α-synuclein and uses thereof. Uses of anti-α-synuclein antibody in detection and diagnostic assays, and for prophylaxis or therapy of α-synuclein-associated neurodegenerative diseases, are also disclosed.
Absstract of: US20260207789A1
0000 The present disclosure relates generally to compositions and methods for determining whether a patient suffers from a traumatic brain injury (TBI) by detecting the presence of an amyloid beta protein in an eye of the patient. Also provided are compositions and methods for preparing a patient for diagnosis and treatment of traumatic brain injury (TB).
Absstract of: AU2024399715A1
The current disclosure provides for methods and compositions for classifying subjects having different biological states. The disclosure describes a method comprising: filtering sequence data obtained from a sample from a subject based on long non-coding RNA (lncRNA) and/or pseudogene RNA (pgRNA), and/or the reference genome; determining a biological state classification of the subject by providing the filtered sequence data to one or more machine learning classifiers as input, wherein the one or more machine learning classifiers is trained to output biological state classifications based on filtered sequence data of a training data set.
Absstract of: US20260210974A1
Methods are provided for classification, diagnosis, prognosis, theranosis, and/or prediction of an outcome following endovascular treatment (EVT) in an individual suffering from an acute ischemic stroke with respect to development of hemorrhagic transformation (HT). The data and integrated model provided herein demonstrates a pre-operative assessment of single-cell biomarkers for accurate prediction of HT following EVT in individuals suffering from acute ischemic strokes. The integrated model incorporates “immune features” such as activation of signaling proteins and/or the frequency of specific cell subset(s). The analysis and prediction of HT is used to guide therapeutic approaches to EVT and the post-treatment care. Specifically, the level of certain features (e.g. elevated prpS6 in memory Th1 CD4+T cells, elevated pCREB in naïve Th1 CD4+T cells and increased frequency of non-classical monocytes) demonstrate an increased likelihood of HT occurring following EVT.
Absstract of: US20260210962A1
0000 Disclosed herein are methods for detecting and treating viral infections. Disclosed is a method of detecting a virus, comprising obtaining a biological sample; capturing a plurality of membranous particles from the biological sample; measuring antigens and nucleic acid levels in the membranous particles or single virions from the biological sample; and measuring an amount of a viral RNA; wherein a virus is detected when the viral protein level or the amount of viral RNA is increased in comparison to a control sample.
Absstract of: US20260210959A1
The present disclosure relates to high density microarrays, methods of manufacturing the arrays, and uses thereof. In particular, the present disclosure provides high density microarrays of biological molecules that allow for specific and sensitive biological assays.
Absstract of: AU2024401251A1
The present application relates to novel b-isox analogs for use in detecting misfolded proteins associated with neurodegenerative diseases, such as ALS, PD, AD, FTLD, and LATE. The present inventors identified and modified a specific site on the b-isox molecule, which significantly enhances detection capabilities. This modification also allows for the selection of analogs that either exhibit low background interference or alter cellular targets, based on the alteration of a functional group at critical site.
Absstract of: US20260210977A1
The invention relates to 5 serum peptide patterns for diagnostics of acute ischemic stroke (AIS) in humans and differential diagnosis from the intracranial hemorrhagic stroke that are defined using a list of the 100 quantitative peptides that in sera of patients with AIS are increased 2 folds or more as compared with individuals without stroke and patients with intracranial hemorrhagic stroke and a list of 54 qualitative peptides detectable in sera of the patients with AIS but not detectable in the sera of individuals without stroke and in sera of patients with intracranial hemorrhagic stroke.
Nº publicación: US20260210975A1 23/07/2026
Applicant:
LONDON HEALTH SCIENCES CENTRE RES INC [CA]
LONDON HEALTH SCIENCES CENTRE RESEARCH INC.
Absstract of: US20260210975A1
0000 A method of determining a risk of developing a neurological disorder in a Long-COVID patient comprising: (a) testing levels of at least one marker associated with a neurologic disorder in a sample taken from the Long-COVID patient, and (b) making a determination that the Long-COVID patient is at risk of developing said neurological disorder when the levels of said at least one marker is increased in the Long-COVID patient compared to healthy control reference levels of said marker. Also a method of determining a risk of developing a cardiometabolic injury in a Long-COVID patient when the levels of expression of a marker associated to a cardiometabolic injury is different in the Long-COVID patient than the levels of said marker in a healthy control. Also methods of treating Long-COVID with a drug effective to mediate the HIF signaling pathway.
BOPI
Electronic site
